The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a rare and complex malignancy of the biliary epithelium. Due to its silent presentation, patients are frequently diagnosed late in their disease course, resulting in poor overall survival. Advances in molecular profiling and targeted therapies have improved medical management, but long-term survival is rarely seen with medical therapy alone. Surgical resection offers a survival advantage, but negative oncologic margins are difficult to achieve, recurrence rates are high, and the need for adequate future liver remnant limits the extent of resection. Advances in neoadjuvant and adjuvant treatments have broadened patient treatment options, and these agents are undergoing active investigation, especially in the setting of advanced, initially unresectable disease. For those who are not able to undergo resection, liver transplantation is emerging as a potential curative therapy in certain cases. Patient selection, favorable tumor biology, and a protocolized, multidisciplinary approach are ultimately necessary for best patient outcomes. This review will discuss the current surgical management of locally advanced, liver-limited intrahepatic cholangiocarcinoma as well as the role of liver transplantation for select patients with background liver disease.

Unresectable Intrahepatic Cholangiocarcinoma Treated with Radiation Segmentectomy/Lobectomy Using Yttrium 90-labeled Glass Microspheres

“…7,8 Data from a recent multi-center database demonstrated 38 months median OS of IHC patients after surgical resection. 13 The current study shows that radiation segmentectomy /lobectomy is inferior to surgical resection in patients with IHC based on these findings. On the other hand, very promising results were observed in 4 patients who survived more than 20 months after radioembolization, and 2 of them survived over 3 and 4 years, respectively.…”

The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review

“…To date, liver transplantation has been established via the Mayo Protocol following neoadjuvant therapy in hCCA. The International Liver Transplantation Society (ILTS) Transplant Oncology Consensus Conference Working Group have recognised the potential role for liver transplantation following neoadjuvant therapy in select patients with iCCA ( 55 ).…”